Selected Research Studies on Linking Imaging Biomarkers with Immunology and Genetic Factors

2023

  • Essenburg C, Browne RW, Ghazal D, Tamaño-Blanco M, Jakimovski D, Weinstock-Guttman B, Zivadinov R, Ramanathan M. Antioxidant defense enzymes in multiple sclerosis: A 5-year follow-up study. Eur J Neurol 2023;(8):2338-2347. [Open Article]
  • Shi T, Browne R, Tamaño-Blanco M, Weinstock-Guttman B, Zivadinov R, Ramanathan M, Hageman Blair R. Metabolomic profiles in relapsing-remitting and progressive multiple sclerosis compared to healthy controls: a five-year follow-up study. Metabol 2023;20;19(5):44. [Open Article]
  • Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, Grigg A, Torkildsen Ø, Bo L, Lehmann AK, Havrdova EK, Krasulova E, Trnený M, Kozak T, van der Walt A, Butzkueven H, McCombe P, Skibina O, Lechner-Scott J, Willekens B, Cartechini E, Ozakbas S, Alroughani R, Kuhle J, Patti F, Duquette P, Lugaresi A, Khoury SJ, Slee M, Turkoglu R, Hodgkinson S, John N, Maimone D, Sa MJ, van Pesch V, Gerlach O, Laureys G, Van Hijfte L, Karabudak R, Spitaleri D, Csepany T, Gouider R, Castillo-Triviño T, Taylor B, Sharrack B, Snowden JA; MSBase Study Group Collaborators; MSBase Study Group Authors; Mrabet S, Garber J, Sanchez-Menoyo JL, Aguera-Morales E, Blanco Y, Al-Asmi A, Weinstock-Guttman B, Fragoso Y, de Gans K, Kermode A; MSBase Study Group. Comparative effectiveness of autologous hematopoieticsStem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis. JAMA Neurol. 2023 Jul 1;80(7):702-713. [Open Article]

2022

  • Siddiqui K, Browne RW, Benedict RHB, Jakimovski D, P Weinstock-Guttman B, Zivadinov R. Ramanathan M. Cholesterol pathway biomarkers are associated with neuropsychological measures in multiple sclerosis. Mult Scler Rel Dis 2022;69:104374. [Open Article]
  • Veerareddy P, Yun JW, Stokes K, Disbrow E, Kevil C, Cvek U, Kilgore Trutschl MP, Ramanathan M, Zivadinov R, Alexander JS. Sulfide metabolism: Vascular inflammatory endothelial biomarkers related to multiple sclerosis. Pathophysiology 2022;29(3):570-582. [Open Article]
  • Jakimovski D, P Gibney B, G Marr K, Ramasamy DP, Dwyer MG, Bergsland N, Weinstock-Guttman B, Ramanathan M, Zivadinov R. Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients. Eur J Neurol 2022;8:2299-2308. [Open Article]
  • Jakimovski D, Zivadinov R, Pelizzari L, Dunne-Jaffe C, Browne RW, Bergsland N, Dwyer MG, Weinstock-Guttman B, Ramanathan M. Plasma 24-hydroxycholesterol is associated with narrower common carotid artery in patients with relapsing multiple sclerosis. Mult Scler Rel Dis 2022;63:103906. [Open Article]

2021

  • McComb M, Browne RW, Bhattacharya S, Bodziak ML, Jakimovski D, Weinstock-Guttman B, Kuhle J, Zivadinov R, Ramanathan M. (2021) The cholesterol autoxidation products, 7-ketocholesterol and 7β-hydroxycholesterol are associated with serum neurofilaments in multiple sclerosis. Mult Scler Relat Disord. 50:102864. [Open article]
  • Uher T, McComb M, Galkin S, Srpova B, Oechtering J, Barro C, Tyblova M, Bergsland N, Krasensky J, Dwyer M, Havrdova EK, Posova H, Vaneckova M, Zivadinov R, Horakova D, Kuhle J, Ramanathan M (2021) Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. Mult Scler 27:220-231 [Open article]
  • Uher T, Havrdova EK, Benkert P, Bergsland N, Krasensky J, Srpova B, Dwyer M, Tyblova M, Meier S, Vaneckova M, Horakova D, Zivadinov R, Leppert D, Kalincik T, Kuhle J (2021) Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. Mult Scler:13524585211047977 [Open article]
  • Jakimovski D, Dwyer MG, Bergsland N, Weinstock-Guttman B, Zivadinov R (2021) Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives. Neurodegener Dis Manag 11:329-340 [Open article]
  • Bergsland N, Dwyer MG, Jakimovski D, Weinstock-Guttman B, Zivadinov R (2021) Diffusion tensor imaging reveals greater microstructure damage in lesional tissue that shrinks into cerebrospinal fluid in multiple sclerosis. J Neuroimaging 31:995-1002 [Open article]
  • Hildesheim FE, Benedict RHB, Zivadinov R, Dwyer MG, Fuchs T, Jakimovski D, Weinstock-Guttman B, Bergsland N (2021) Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis. J Neurol [Open article]
  • Hildesheim FE, Ramasamy DP, Bergsland N, Jakimovski D, Dwyer MG, Hojnacki D, Lizarraga AA, Kolb C, Eckert S, Weinstock-Guttman B, Zivadinov R (2021) Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. Mult Scler Relat Disord 47:102653 [Open article]
  • Bergsland N, Benedict RHB, Dwyer MG, Fuchs TA, Jakimovski D, Schweser F, Tavazzi E, Weinstock-Guttman B, Zivadinov R (2021) Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Cross-Sectional Structural MRI Study. J Magn Reson Imaging 53:731-739 [Open article]

2020

  • Ziliotto N, Zivadinov R, Jakimovski D, et al. Relationships Among Circulating Levels of Hemostasis Inhibitors, Chemokines, Adhesion Molecules, and MRI Characteristics in Multiple Sclerosis. Front Neurol 2020;11:553616. [Open article]
  • Jakimovski D, Zivadinov R, Dwyer MG, et al. High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis. J Neurol Sci 2020;418:117120. [Open article]
  • Jakimovski D, Bergsland N, Dwyer MG, Ramasamy DP, Ramanathan M, Weinstock-Guttman B, Zivadinov R (2020) Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis. Diagnostics (Basel) 10 [Open article]
  • McComb M, Krikheli M, Uher T, et al. Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. J Clin Lipidol 2020. [Open article]
  • McComb M, Parambi R, Browne RW, et al. Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis. Mult Scler Relat Disord 2020;45:102389. [Open article]
  • Tavazzi E, Jakimovski D, Kuhle J, et al. Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study. Neurol Neuroimmunol Neuroinflamm 2020;7:e737. [Open article]
  • Tavazzi E, Zivadinov R, Dwyer MG, et al. MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. Expert Rev Neurother 2020;20:821-834. [Open article]
  • Uher T, Schaedelin S, Srpova B, et al. Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurol Neuroimmunol Neuroinflamm 2020;7:e714. [Open article]
  • Jakimovski D, Weinstock-Guttman B, Ramanathan M, Dwyer MG and Zivadinov R (2020). Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective. Vaccines (Basel) 8(1). [Open article]
  • Tavazzi E, Bergsland N, Kuhle J, et al. A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. J Neurol 2020;267:802-811. [Open article]
  • Jakimovski D, Zivadinov R, Ramanthan M, et al. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. Mult Scler 2020;26:1670-1681. [Open article]
  • Jakimovski D, Zivadinov R, Pelizzari L, Browne RW, Weinstock-Guttman B, Ramanathan M (2020) Lipoprotein(a) Levels Are Associated with the Size of Extracranial Arteries in Multiple Sclerosis. J Vasc Res 57:16-23 [Open article]
  • Murali N, Browne RW, Fellows Maxwell K, Bodziak ML, Jakimovski D, Hagemeier J, Bergsland N, Weinstock-Guttman B, Zivadinov R and Ramanathan M (2020). Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up. Eur J Neurol 27(1): 188-e184. [Open article]
  • Jakimovski D, Ramanathan M, Weinstock-Guttman B, et al. Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study. Mult Scler 2020;26:322-332. [Open article]

2019

  • Zivadinov R, Ramanathan M, Hagemeier J, Bergsland N, Ramasamy DP, Durfee J, Kolb C and Weinstock-Guttman B (2019). Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis. Mult Scler Relat Disord 36: 101388. [Open article]
  • Jakimovski D, Kuhle J, Ramanathan M, Barro C, Tomic D, Hagemeier J, Kropshofer H, Bergsland N, Leppert D, Dwyer MG, Michalak Z, Benedict RHB, Weinstock-Guttman B and Zivadinov R (2019). Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. Ann Clin Transl Neurol 6(9): 1757-1770. [Open article]
  • Browne RW, Jakimovski D, Ziliotto N, Kuhle J, Bernardi F, Weinstock-Guttman B, Zivadinov R and Ramanathan M (2019). High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: A fatigue-metabolism nexus? J Clin Lipidol 13(4): 654-663 e651. [Open article]
  • Zivadinov R and Dwyer MG (2019). Network Dynamics and Cognitive Impairment in Multiple Sclerosis: Functional MRI-based Decoupling of Complex Relationships. Radiology 292(2): 458-459. [Open article]
  • Fellows Maxwell K, Bhattacharya S, Bodziak ML, Jakimovski D, Hagemeier J, Browne RW, Weinstock-Guttman B, Zivadinov R and Ramanathan M (2019). Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study. J Lipid Res 60(7): 1190-1198. [Open article]
  • Ziliotto N, Bernardi F, Jakimovski D and Zivadinov R (2019). Coagulation Pathways in Neurological Diseases: Multiple Sclerosis. Front Neurol 10: 409. [Open article]
  • Ziliotto N, Zivadinov R, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Ramanathan M, Marchetti G and Bernardi F (2019). Are Plasma Levels of Vascular Adhesion Protein-1 Associated Both with Cerebral Microbleeds in Multiple Sclerosis and Intracerebral Haemorrhages in Stroke? Thromb Haemost 119(1): 175-178. [Open article]
  • Guan Y, Jakimovski D, Ramanathan M, Weinstock-Guttman B and Zivadinov R (2019). The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging. Neural Regen Res 14(3): 373-386. [Open article]
  • Ziliotto N, Zivadinov R, Jakimovski D, Baroni M, Tisato V, Secchiero P, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Bernardi F, Ramanathan M and Marchetti G (2019). Plasma levels of soluble NCAM in multiple sclerosis. J Neurol Sci 396: 36-41. [Open article]
  • Jakimovski D, Topolski M, Kimura K, Marr K, Gandhi S, Ramasamy DP, Bergsland N, Hagemeier J, Weinstock-Guttman B and Zivadinov R (2019). Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena? Clin Auton Res 29(3): 329-338. [Open article]

2018

  • Ziliotto N, Bernardi F, Jakimovski D, Baroni M, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zamboni P, Marchetti G, Zivadinov R and Ramanathan M (2018). Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis patients. Mult Scler Relat Disord 25: 37-42. [Open article]
  • Ziliotto N, Bernardi F, Jakimovski D, Baroni M, Marchetti G, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Schweser F, Zamboni P, Ramanathan M and Zivadinov R (2018). Hemostasis biomarkers in multiple sclerosis. Eur J Neurol 25(9): 1169-1176. [Open article]

2017

  • Uher T, Fellows K, Horakova D, Zivadinov R, Vaneckova M, Sobisek L, Tyblova M, Seidl Z, Krasensky J, Bergsland N, Weinstock-Guttman B, Havrdova E and Ramanathan M (2017). Serum lipid profile changes predict neurodegeneration in interferon-beta1a-treated multiple sclerosis patients. J Lipid Res 58(2): 403-411. [Open article]
  • Mukhopadhyay S, Fellows K, Browne RW, Khare P, Krishnan Radhakrishnan S, Hagemeier J, Weinstock-Guttman B, Zivadinov R and Ramanathan M (2017). Interdependence of oxysterols with cholesterol profiles in multiple sclerosis. Mult Scler 23(6): 792-801. [Open article]

2016

  • Zivadinov R, Cerza N, Hagemeier J, Carl E, Badgett D, Ramasamy DP, Weinstock-Guttman B and Ramanathan M (2016). Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS. Neurol Neuroimmunol Neuroinflamm 3(1): e190. [Open article]
  • Uher T, Horakova D, Tyblova M, Zeman D, Krasulova E, Mrazova K, Seidl Z, Vaneckova M, Krasensky J, Weinstock-Guttman B, Ramanathan M, Havrdova E and Zivadinov R (2016). Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. Mult Scler 22(6): 770-781. [Open article]

2015

  • Dwyer MG, Zivadinov R, Tao Y, Zhang X, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Weinstock-Guttman B, Hayward B, Dangond F and Markovic-Plese S (2015). Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. BMC Neurol 15: 232. [Open article]
  • Fellows K, Uher T, Browne RW, Weinstock-Guttman B, Horakova D, Posova H, Vaneckova M, Seidl Z, Krasensky J, Tyblova M, Havrdova E, Zivadinov R and Ramanathan M (2015). Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. J Lipid Res 56(10): 2010-2018. [Open article]
  • Malyavantham K, Weinstock-Guttman B, Suresh L, Zivadinov R, Shanahan T, Badgett D and Ramanathan M (2015). Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis. PLoS One 10(6): e0129503. [Open article]
  • Narayanaswamy R, Iyer V, Khare P, Bodziak ML, Badgett D, Zivadinov R, Weinstock-Guttman B, Rideout TC, Ramanathan M and Browne RW (2015). Simultaneous Determination of Oxysterols, Cholesterol and 25-Hydroxy-Vitamin D3 in Human Plasma by LC-UV-MS. PLoS One 10(4): e0123771. [Open article]

2014

  • Browne RW, Weinstock-Guttman B, Zivadinov R, Horakova D, Bodziak ML, Tamano-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Qu J, Havrdova E and Ramanathan M (2014). Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. J Steroid Biochem Mol Biol 143: 424-433. [Open article]
  • Zivadinov R, Chin J, Horakova D, Bergsland N, Weinstock-Guttman B, Tamano-Blanco M, Badgett D, Hagemeier J, Tyblova M, Carl E, Krasensky J, Vaneckova M, Seidl Z, Dwyer MG, Havrdova E and Ramanathan M (2014). Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study. J Neuroimmunol 273(1-2): 58-64. [Open article]
  • Browne RW, Weinstock-Guttman B, Horakova D, Zivadinov R, Bodziak ML, Tamano-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Havrdova E and Ramanathan M (2014). Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. J Neurol Neurosurg Psychiatry 85(8): 859-864. [Open article]

2013

  • Beggs C, Chung CP, Bergsland N, Wang PN, Shepherd S, Cheng CY, Dwyer MG, Hu HH and Zivadinov R (2013). Jugular venous reflux and brain parenchyma volumes in elderly patients with mild cognitive impairment and Alzheimer's disease. BMC Neurol 13(1): 157. [Open article]
  • Weinstock-Guttman B, Horakova D, Zivadinov R, Tamano-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Havrdova E and Ramanathan M (2013). Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. J Neuroimmunol 263(1-2): 121-127. [Open article]
  • Weinstock-Guttman B, Zivadinov R, Horakova D, Havrdova E, Qu J, Shyh G, Lakota E, O'Connor K, Badgett D, Tamano-Blanco M, Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z and Ramanathan M (2013). Lipid profiles are associated with lesion formation over 24 months in interferon-beta treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry 84(11): 1186-1191. [Open article]
  • Kardys A, Weinstock-Guttman B, Dillon M, Masud MW, Weinstock N, Mahfooz N, Lang JK, Weinstock A, Lincoff N, Zivadinov R and Ramanathan M (2013). Cholesterol affects retinal nerve fiber layer thickness in patients with multiple sclerosis with optic neuritis. Eur J Neurol 20(9): 1264-1271. [Open article]
  • Zivadinov R, Treu CN, Weinstock-Guttman B, Turner C, Bergsland N, O'Connor K, Dwyer MG, Carl E, Ramasamy DP, Qu J and Ramanathan M (2013). Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. J Neurol Neurosurg Psychiatry 84(10): 1075-1081. [Open article]
  • Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Qu J, Tamano-Blanco M, Badgett D, Tyblova M, Bergsland N, Hussein S, Willis L, Krasensky J, Vaneckova M, Seidl Z, Lelkova P, Dwyer MG, Zhang M, Yu H, Duan X, Kalincik T and Ramanathan M (2013). Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. PLoS One 8(1): e53996. [Open article]

2012

  • Zivadinov R, Ramanathan M, Ambrus J, Hussein S, Ramasamy DP, Dwyer MG, Bergsland N, Minagar A and Weinstock-Guttman B (2012). Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. Neurol Res 34(8): 761-769. [Open article]

2011

  • Weinstock-Guttman B, Zivadinov R, Mahfooz N, Carl E, Drake A, Schneider J, Teter B, Hussein S, Mehta B, Weiskopf M, Durfee J, Bergsland N and Ramanathan M (2011). Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation 8: 127. [Open article]
  • Weinstock-Guttman B, Zivadinov R and Ramanathan M (2011). Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis." J Neurol Sci 311(1-2): 86-91. [Open article]
  • Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Tamano-Blanco M, Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z, Lelkova P and Ramanathan M (2011). HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. J Neuroimmunol 236(1-2): 76-80. [Open article]
  • Weinstock-Guttman B, Zivadinov R, Qu J, Cookfair D, Duan X, Bang E, Bergsland N, Hussein S, Cherneva M, Willis L, Heininen-Brown M and Ramanathan M (2011). Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 82(2): 189-195. [Open article]
  • Weinstock-Guttman B, Benedict RH, Tamano-Blanco M, Ramasamy DP, Stosic M, Polito J, Zivadinov R and Ramanathan M (2011). The rs2030324 SNP of brain-derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis. Pathophysiology 18(1): 43-52. [Open article]

2010

  • Horakova D, Kyr M, Havrdova E, Dolezal O, Lelkova P, Pospisilova L, Bergsland N, Dwyer MG, Cox JL, Hussein S, Seidl Z, Vaneckova M, Krasensky J and Zivadinov R (2010). Apolipoprotein E epsilon4-positive multiple sclerosis patients develop more gray-matter and whole-brain atrophy: a 15-year disease history model based on a 4-year longitudinal study. Folia Biol (Praha) 56(6): 242-251. [Open article]
  • Horstman LL, Jy W, Ahn YS, Zivadinov R, Maghzi AH, Etemadifar M, Steven Alexander J and Minagar A (2010). Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation 7: 10. [Open article]

2009

  • Zivadinov R, Weinstock-Guttman B, Zorzon M, Uxa L, Serafin M, Bosco A, Bratina A, Maggiore C, Grop A, Tommasi MA, Srinivasaraghavan B and Ramanathan M (2009). Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J Neuroimmunol 209(1-2): 123-130. [Open article]
  • Zivadinov R, Zorzon M, Weinstock-Guttman B, Serafin M, Bosco A, Bratina A, Maggiore C, Grop A, Tommasi MA, Srinivasaraghavan B and Ramanathan M (2009). Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 80(6): 620-625. [Open article]

2008

  • Sternberg Z, Weinstock-Guttman B, Hojnacki D, Zamboni P, Zivadinov R, Chadha K, Lieberman A, Kazim L, Drake A, Rocco P, Grazioli E and Munschauer F (2008). Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. Mult Scler 14(6): 759-763. [Open article]

2007

  • Weinstock-Guttman B, Zivadinov R, Tamano-Blanco M, Abdelrahman N, Badgett D, Durfee J, Hussein S, Feichter J, Patrick K, Benedict R and Ramanathan M (2007). Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. J Neuroimmunol 188(1-2): 167-174. [Open article]
  • Zivadinov R, Uxa L, Bratina A, Bosco A, Srinivasaraghavan B, Minagar A, Ukmar M, Benedetto S and Zorzon M (2007). HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. Int Rev Neurobiol 79: 521-535. [Open article]
  • Garg N, Zivadinov R, Ramanathan M, Vasiliu I, Locke J, Watts K, Lema J, Rajeswary J, Munschauer FE, Ambrus J, Jr. and Weinstock-Guttman B (2007). Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol 187(1-2): 159-165. [Open article]
  • Weinstock-Guttman B, Tamano-Blanco M, Bhasi K, Zivadinov R and Ramanathan M (2007). Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients. J Neuroimmunol 182(1-2): 236-239. [Open article]

2006

  • Zivadinov R, Nasuelli D, Tommasi MA, Serafin M, Bratina A, Ukmar M, Pirko I, Johnson AJ, Furlan C, Pozzi-Mucelli RS, Monti-Bragadin L, Grop A, Zambon M, Antonello RM, Cazzato G and Zorzon M (2006). Positivity of cytomegalovirus antibodies predicts a better clinical and radiological outcome in multiple sclerosis patients. Neurol Res 28(3): 262-269. [Open article]

2004

  • Bagnato F, Zivadinov R, Cecchinelli D, Tancredi A, Grop A, Pierallini A, De Lena C, Prencipe M, Reale G, Zorzon M and Millefiorini E (2004). beta2-microglobulin serum level is not a marker of disease activity in multiple sclerosis. Eur J Neurol 11(7): 455-460. [Open article]
  • Fiotti N, Zivadinov R, Altamura N, Nasuelli D, Bratina A, Tommasi MA, Bosco A, Locatelli L, Grop A, Cazzato G, Guarnieri G, Giansante C and Zorzon M (2004). MMP-9 microsatellite polymorphism and multiple sclerosis. J Neuroimmunol 152(1-2): 147-153. [Open article]

2003

  • Zivadinov R, Uxa L, Zacchi T, Nasuelli D, Ukmar M, Furlan C, Pozzi-Mucelli R, Tommasi MA, Locatelli L, Ulivi S, Bratina A, Bosco A, Grop A, Cazzato G and Zorzon M (2003). HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. J Neurol 250(9): 1099-1106. [Open article]